Gene Therapy for Long QT Syndrome: Fact or Fiction?

  • P. J. Schwartz
Conference paper


For many years the therapy for long QT syndrome (LQTS) has been based on simple and sound principles [1, 2]. In essence, therapy had been guided by the time-honored concept that it has to reflect understanding of the mechanisms, underlying or precipitating the main symptoms. In those happy days things were simple, we thought that we were dealing with one disease, and we were assuming that the precipitating events were more or less the same for all patients; the gen- erally accepted common pathway for the initiation of the life-threatening arrhythmias of LQTS was represented by a sudden neural release of norepineph- rine secondary to an abrupt activation of the sympathetic nervous system [2].


Brugada Syndrome Sympathetic Denervation Sodium Channel Gene Cardiac Sympathetic Denervation Left Cardiac Sympathetic Denervation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schwartz PJ, Periti M, Malliani A (1975) The long Q-T syndrome. Am Heart J 89:378–390PubMedCrossRefGoogle Scholar
  2. 2.
    Schwartz PJ (1985) Idiopathic long QT syndrome: progress and questions. Am Heart J 109:399–411PubMedCrossRefGoogle Scholar
  3. 3.
    Moss AJ, McDonald J (1971) Unilateral cervicothoracic sympathetic ganglionec-tomy for the treatment of long QT interval syndrome. N Engl J Med 285:903–904PubMedCrossRefGoogle Scholar
  4. 4.
    Schwartz PJ, Locati EH, Moss AJ, Crampton RS, Trazzi R, Ruberti U (1991) Left car-diac sympathetic denervation in the therapy of congenital long QT syndrome: a worldwide report. Circulation 84:503–511PubMedCrossRefGoogle Scholar
  5. 5.
    Roden DM, Lazzara R, Rosen MR, Schwartz PJ, Towbin JA, Vincent GM, for the SADS Foundation Task Force on LQTS (1996) Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. Circulation 94:1996– 2012Google Scholar
  6. 6.
    Priori SG, Barhanin J, Hauer RNW, Haverkamp W, Jongsma HJ, Kleber AG, McKenna WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde AM (1999) Genetic and molecular basis of cardiac arrhythmias: impact on clinical management. Part I and II. Circulation 99:518-528; Part III. Circulation 99:674–681Google Scholar
  7. 7.
    Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantù F, Towbin AJ, Keating MT, Hammoude H, Brown AM, Chen LK, Colatsky TJ (1995) Long QT syndrome patients with mutations on the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-spe-cific therapy. Circulation 92:3381–3386Google Scholar
  8. 8.
    Bennett PB, Yazawa K, Makita N, George AL Jr (1995) Molecular mechanism for an inherited cardiac arrhythmia. Nature 376:683–685PubMedCrossRefGoogle Scholar
  9. 9.
    Dumaine R, Wang Q, Keating MT, Hartmann HA, Schwartz PJ, Brown AM, Kirsch GE (1996) Multiple mechanisms of Na+ channel-linked long-QT syndrome. Circ Res 78:916–924PubMedCrossRefGoogle Scholar
  10. 10.
    Rosero SZ, Zareba W, Robinson JL, Moss AJ (1997) Gene-specifìc therapy for long QT syndrome: QT shortening with lidocaine and tocainide in patients with muta-tion of the sodium channel gene. ANE 3:274–278Google Scholar
  11. 11.
    An RH, Wang XL, Kerem B, Benhorin J, Medina A, Goldmit M, Kass RS (1998) Novel LQT-3 mutation affects Na+ channel activity through interactions between a-and β1-subunits. Circ Res 83:141–146CrossRefGoogle Scholar
  12. 12.
    Compton SJ, Lux RL, Ramsey MR, Strelich KT, Sanguinetti MC, Green LS, Keating MT, Mason JW (1996) Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 94:1018–1022Google Scholar
  13. 13.
    Sanguinetti MC, Curran ME, Spector PS, Keating MT (1996) Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci USA 93:2208–2212PubMedCrossRefGoogle Scholar
  14. 14.
    Tan HL, Alings M, Van Olden RW, Wilde AAM (1999) Long-term (subacute) potas-sium treatment in congenital HERG-related long QT syndrome (LQTS2). J Cardiovasc Electrophysiol 10:229–233PubMedCrossRefGoogle Scholar
  15. 15.
    Schwartz PJ (1997) The long QT syndrome. In: Camm AJ (ed) Clinical approaches to tachyarrhythmias series. Futura, Armonk, NYGoogle Scholar
  16. 16.
    Schwartz PJ, Priori SG, Napolitano C. Long QT syndrome. In: Zipes DP, Jalife J (eds) Cardiac electrophysiology. From cell to bedside, 3rd edn. WB Saunders, Philadelphia (in press)Google Scholar
  17. 17.
    Schwartz PJ, Moss AJ, Priori SG, Wang Q, Lehmann MH, Timothy K, Denjoy I, Haverkamp W, Guicheney P, Paganini V, Scheinman MM, Karnes PS (1997) Gene-specific influence on the triggers for cardiac arrest in the long QT syndrome. Circulation 96[Suppl]:212 (abstr)CrossRefGoogle Scholar
  18. 18.
    Priori SG, Napolitano C, Locati EH, Cantù F, Stramba-Badiale M, Keating MT, Towbin JA, Colatsky TJ, Chen LK, Schwartz PJ (1996) Long QT syndrome patients genetically linked to defective genes on chromosomes 11, 7 and 3 present differential response to changes in heart rate. J Am Coll Cardiol 27[Suppl A]:171ACrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • P. J. Schwartz
    • 1
  1. 1.Dipartimento di Cardiologia, Policlinico S. Matteo, IRCCS eUniversità di PaviaItaly

Personalised recommendations